Document:

<PAGE>

                                                                    EXHIBIT 10.4

           AMENDMENT #1 TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT

         This Amendment effective as of the last date on the signature page
hereof, by and between Cima Labs, Inc. ("CIMA") and Schering-Plough Ltd.
("SCHERING") amends and supplements that certain Development, License and Supply
Agreement between CIMA and SCHERING dated May 20, 2002 (the "Agreement").

         WHEREAS, CIMA has performed certain aspects of the Development Program
under the Outside Service Agreement (as such term is defined in the Agreement),
and is performing and will continue to perform development work relating to the
Licensed Product (as such term is defined in the Agreement) under the
Development Program (as such term is defined in the Agreement) for SCHERING
under the Agreement;

         WHEREAS, the parties have agreed to modify the development and
milestone payments under the Agreement; and

         WHEREAS the parties also desire to set forth, confirm and memorialize
certain oral understandings of the parties relating to certain aspects of the
Development Program that were not completed under the Outside Services Agreement
and that have been or will be completed under the Agreement.

         NOW, THEREFORE, in consideration of the mutual covenants contained in
this Amendment, the parties hereby agree to amend the Agreement as follows:

         1.       Except as expressly defined herein, all capitalized terms
shall have the meanings set forth in the Agreement.

         2.       The Agreement, including but not limited to Section 2.3, is
amended to provide that certain development work contemplated by the Outside
Services Agreement has been performed by CIMA for SCHERING since April 1, 2002
and will be performed in the future by the parties to the Agreement. CIMA
acknowledges that the Outside Services Agreement expired by its own terms on
March 31, 2002, and has not been amended. CIMA agrees that Schering-Plough
Research Institute had no further obligations under the Outside Services
Agreement as of March 31, 2002, and that Schering-Plough Research Institute
fully performed its obligations under the Outside Services Agreement. CIMA
releases any claims it has or may have against Schering-Plough Research
Institute relating to or arising from the Outside Services Agreement, and agrees
that in the event CIMA has any claim relating to the Development Program, CIMA
shall look solely to SCHERING with respect to any such claim.

         3.       CIMA acknowledges receipt of [***CONFIDENTIAL TREATMENT
REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION.***] pursuant to Section IV.a of Appendix C, and agrees that it shall
[***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.***] as required by the Development Program.
Among other things, SCHERING will pay, as set forth below, [***CONFIDENTIAL
TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES

<PAGE>

AND EXCHANGE COMMISSION.***] more than originally contemplated in Appendix C for
the development program, to reflect the parties' agreement regarding the fees
for the manufacture of the [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.***]. SCHERING will
also pay an additional [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.***] for the
manufacture of [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.***]. SCHERING will pay
CIMA [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.***]. The payments and timelines for the
Development Program, as set forth in Appendix C, are deleted. The monies to be
paid to CIMA for completion of the Development Program will be paid as set forth
in paragraph 4 below, which paragraph amends and supercedes Section 3.1 of the
Agreement. Without limiting the foregoing, CIMA agrees that three invoices
submitted to SCHERING, each in the amount of [***CONFIDENTIAL TREATMENT
REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION.***] (invoices 16212, 16363 and 16589, respectively), for partial
payment of certain development work under Section IIa of Appendix C, as well as
a credit memo submitted to SCHERING in the amount of [***CONFIDENTIAL TREATMENT
REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION.***] (invoice 16593), are withdrawn, and no payment is due. CIMA will
invoice SCHERING for all such payments in accordance with the terms of the
Agreement.

         4.       Section 3.1 of the Agreement is deleted and replaced with the
following:

                  3.1      Consideration for License. In partial consideration
                  for the licenses granted to Schering hereunder, Schering shall
                  make the following payments to CIMA on the first occurrence of
                  the indicated triggering events.

                           $250,000 Paid on 7/11/02

                           $250,000    [***CONFIDENTIAL TREATMENT REQUESTED,
                                       PORTION OMITTED FILED SEPARATELY WITH THE
                                       SECURITIES AND EXCHANGE COMMISSION.***]
                                       (paid 01/23/02)

                           [***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED
                           FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
                           COMMISSION.***]

Each of the milestones payments set forth in this Section 3.1 shall be payable
once upon the initial achievement of such event and no amounts shall be due
hereunder for subsequent or repeated achievement of such event. In addition, the
parties recognize that Schering SOP 1056 may be modified during the Term. In
such event, SCHERING shall give CIMA prompt notice and a copy of such
modification, and the parties will agree on payment of the additional costs, if
any, relating to the modification of Schering SOP 1056, as well as the schedule
modifications, if any. Payment and timing of the [***CONFIDENTIAL

<PAGE>

TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.***] milestone above that incorporates Schering SOP 1056
will not be modified, unless otherwise agreed by the parties in writing.

         5.       In the event of any conflict between this Amendment and the
Agreement, the terms of this Amendment shall control.

         6.       In the event that Schering terminates this Agreement under
Section 15.2(a), then within thirty (30) days of the termination date Schering
shall pay CIMA for all development activities completed by CIMA prior to the
termination date based upon the payments for the Development Program as set
forth in Appendix C the "Agreement, and any additional development activities
and payments specified by this Amendment or future amendments.

         7.       Unless otherwise set forth in this Amendment, all references
to Sections or Appendices refer to Sections or Appendices of the Agreement.

         8.       All other terms and conditions of the Agreement shall remain
in full force and effect.

         IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
executed in three originals by their duly authorized representatives.

CIMA LABS, INC.                                       SCHERING-PLOUGH LTD.

BY: /s/ John M. Siebert                               BY: /s/ David Poorvin
    -----------------------------                         ------------------

NAME: John M. Siebert                                 NAME: David Poorvin, Ph.D.

TITLE: President & CEO                                TITLE: Prokurist

DATE: 18 April 2003                                   DATE: 2 May 2003

<PAGE>

                                   EXHIBIT 1

[***CONFIDENTIAL TREATMENT REQUESTED, PORTION OMITTED FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.***]<PAGE>
                                                                    EXHIBIT 10.5

                            [ASTRAZENECA LETTERHEAD]

John Siebert
CIMA Laboratories Inc

                                                                  29 August 2002

Our Ref:                        Your Ref:   Tel:                 Fax:
Agt/Comm/Cima/Lic & Supply                  +44 1625 230089      +44 1625 514061

Dear John

LICENSE AGREEMENT DATED 28 MAY 1999 BETWEEN CIMA LABORATORIES INC AND IPR
PHARMACEUTICALS INC (THE "AGREEMENT")

We note that the Agreement historically refers to OraSolv Technology in relation
to the production of fastmelt tablets and are aware that under the resulting
Supply Agreement, DuraSolv Technology is being utilized to produce fastmelt
tablets. We therefore would appreciate it if you could sign and return a copy of
this letter to us to confirm that the definition of OraSolv Technology in the
Agreement includes the DuraSolv Technology used at present (plus any associated
improvements as defined in the Agreement) in the manufacture of Zomig Rapimelt
tablets.

Many thanks for your assistance in this clarification.

Yours sincerely,

Ken Tinebo
Supply Chain & Logistics

Signed and Accepted on behalf of CIMA Laboratories Inc by

/s/ John M. Siebert                        30 Aug, 2002
-------------------------------------------------------
John Siebert<PAGE>
                                                                    EXHIBIT 10.6

                             [AKZO NOBEL LETTERHEAD]

January 31, 2001

John M. Siebert, Ph.D.
President
CIMA Labs Inc.
10000 Valley View Road
Eden Prairie, MN 55344

Re:  License Agreement

Dear Dr. Siebert:

This is to confirm certain understandings reached between Organon
(International) AG and N.V. Organon (collectively referred to as "Organon") and
CIMA Labs Inc. ("CIMA") with respect to Article 16.11 of the License Agreement
entered into by and between Organon and CIMA on December 29, 1999 ("the
Agreement").

We have discussed the fact that the date currently envisaged in Article 16.11 of
the Agreement is not feasible. Accordingly, Article 16.11 of the Agreement shall
be modified as follows: The phrase "Effective Date" shall be deleted and
replaced with the phrase "from January 15, 2001..."

All other terms and conditions of the Agreement shall remain the same.

<PAGE>

                             [AKZO NOBEL LOGO]

Please indicate your acceptance of and agreement to the foregoing by signing and
returning to us two duplicate originals of this letter. The other original may
be kept for your files.

Very truly yours,

                           ORGANON (INTERNATIONAL) AG

By:   /s/ [illegible]                          By:   /s/ [illegible]
      --------------------------------               ---------------------------

Title:  General Manager                        Title:  General Manager
      --------------------------------               ---------------------------

                                  N.V. ORGANON

By:  /s/ T. Kalff                              By:   /s/ J. Lakeman
     ----------------------------------              ---------------------------
     Drs. T. Kalff                                   Dr. J. Lakeman
Title:  President                              Title:  Managing Director
      --------------------------------               ---------------------------

Agreed to and accepted as
of the date first written above:

                                 CIMA LABS INC.

By:
   -----------------------------------

Title:
      --------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]